Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ibrutinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 10
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 10 pipeline programs matching "ibrutinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

10 results for “ibrutinib” Back to intelligence hub

Search results

  1. Ibrutinib

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial
  2. Ibrutinib hard capsule for oral use, Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial
  3. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria

    phase 3 small molecule active

    1 trial
  4. Remibrutinib

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial
  5. IBRUTINIB

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis

    phase 2 small molecule active

    1 trial
  6. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial
  7. Ibrutinib

    United Therapeutics Europe Ltd

    Asymptomatic COVID-19 Infection Laboratory-Confirmed

    phase 2 small molecule terminated

    1 trial
  8. Ibrutinib 560 mg

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial
  9. R-EPOCH in Combination With Ibrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Richter Transformation

    phase 2 small molecule active

    1 trial
  10. Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.